Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E. coli asparaginase: a retrospective analysis within the ALL-BFM trials
Authors:
O. Hrodek
Published in:
Transfuze Hematol. dnes,18, 2012, No. 1, p. 47.
Category:
Selection of press reports and books
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2012 Issue 1
Most read in this issue
- Asymptomatic pituitary macroadenoma oppressing optic chiasm – ‘incidentaloma‘ – identified within diagnostical staging of patient with primary extranodal diffuse large B-cell lymphoma of orbit and paranasal sinuses – a case report
- The role of physical activity in patients suffering from haematological malignancies
- Mobilization of hematopoetic stem cells using plerixafor - experience of the Czech Republic transplantation centers
- Prevalence of red blood cell and HLA antibodies in multi-transfused haematological patients